The news media during May has been dominated by coverage of the tragic drilling rig explosion and resulting massive oil spill
in the Gulf of Mexico. If the event weren't so catastrophic, one would be tempted to smile at the irony that the explosion
and spill occurred just weeks after President Obama had thrown his support behind continued offshore oil drilling off the
US coast, a move that dismayed his supporters on the left while gaining no new friends on the right. The President's support
for offshore drilling was intended to help the US meet its long-term energy needs, but the Gulf disaster could put a halt
to all offshore exploration and drilling for decades to come. As a result, the petroleum industry may have ingloriously succeeded
in "snatching defeat from the jaws of victory."
The events in the Gulf of Mexico are an example of what New York University professor Nassim Taleb has called a "black swan"
event. Taleb defines black swans as positive or negative events that are highly improbable but have extreme consequences. He argues that over the centuries
black swans, and the responses to them, have largely shaped the world in which we live. They are statistical outliers, very
unlikely to happen, but with immense ramifications when they do. Taleb argues that while we painstakingly develop explanations
for the black swans after they occur, their very improbability causes us to spend too little time thinking about how we might
mitigate their consequences—or take advantage of the opportunities they present—if they do occur.
SHAPING THE BIO/PHARMA INDUSTRY
It is certainly the case that black swan events have shaped the evolution of the bio/pharmaceutical industry. Some of the
industry's most successful products have been the result of low probability or unexpected events, e.g., Alexander Fleming's
accidental discovery of penicillin; the unexpected side effects of sildenafil, a candidate for the treatment of cardiovascular
diseases that became Viagra; and the spate of flu epidemics in the last decade, which spurred the explosion of vaccine development.
Just as importantly, black swan events have shaped the regulatory and clinical research environment that governs the bio/pharmaceutical
industry. The original Food, Drug and Cosmetics Act was passed as a result of deaths caused by the adulteration of drugs
with ethylene glycol in the early twentieth century, and the modern drug research regime, with its focus on safety and efficacy,
was an outgrowth of the unexpected side effects of thalidomide in the 1950s and 1960s. The FDA's current initiative for postapproval
monitoring of new drugs, Risk Evaluation and Mitigation Strategies, followed the unexpected side effects that appeared with
widespread use of Cox-2 inhibitors. Most recently, the heparin scare of two years gave rise to initiatives to ensure the safety
and security of inputs across the supply chain.
The global financial crisis has certainly been a black swan event for contract services companies. Providers of research,
development and manufacturing services experienced an almost unbroken string of good years during the past decade, as venture
capital and public equity poured into early-stage companies and global bio/pharmaceutical companies spent heavily to replace
drugs soon to go off patent. The common wisdom was that the bio/pharmaceutical industry was recession-proof, and no one gave
much thought to the possibility that the party could end.
The global financial crisis sure changed things, however. Investors and global bio/pharmaceutical companies became more risk-averse,
and the flow of funds to support R&D at both large and small bio/pharmaceutical companies slowed considerably. Contract research
and manufacturing service providers (CROs and CMOs) that were used to double-digit revenue and profit growth began experiencing
double-digit revenue and profit declines. A number of marginal companies have gone out of business and more are likely in